Symbol | Exchange | Currency |
|---|
Precision BioSciences, Inc. (Nasdaq: NASDAQ:DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today...
Precision BioSciences, Inc. (Nasdaq: NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today...
Precision BioSciences, Inc. (Nasdaq: NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today...
Amgen Inc (NASDAQ:AMGN). AMGN announced that it has entered into a research collaboration agreement with Massachusetts-based private biotech Generate Biomedicines to discover and...
ACADIA Pharmaceuticals (NASDAQ:ACAD) Inc. ACAD announced that it intends to resubmit the supplemental new drug application (sNDA) for its marketed drug, Nuplazid (pimavanserin),...
As of late, it has definitely been a great time to be an investor inPrecision BioSciences, Inc. (NASDAQ:DTIL) . The stock has moved higher by more than 100% in the past month,...
Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. ARCUS is designed to be precise in its specificity and versatile in its design for gene knock out as well as complex edits with gene insertion and gene repair. ARCUS is also relatively small size, which potentially allows delivery to a range of cells and tissues using viral and non-viral gene delivery methods. Genome editing is a biotechnology process that removes, inserts or repairs a portion of deoxyribonucleic acid (DNA) at a specific location in a cell’s genome. There are two primary mechanisms of DNA repair, non-homologous end joining, and homology directed repair. There are several genomes editing technologies, including ARCUS, zinc-finger nucleases, TAL-effector nucleases, CRISPR/Cas9, and base editors.
| Average | 6.29 (+666.55% Upside) |
| High | 17.00 |
| Low | 1.00 |
| Price | 0.82 |
| No. of Analysts | 7 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Buy | Strong Sell |
| Technical Indicators | Buy | Strong Buy | Strong Buy | Buy | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 9.45 | 9.46 | 9.45 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 18.70 | 18.74 | 17.53 | +1.05 | +5.95% | 844.81K | NASDAQ | |||
| 12.80 | 12.85 | 12.69 | +0.03 | +0.23% | 106.25K | NASDAQ | |||
| 35.40 | 35.53 | 34.54 | +0.64 | +1.84% | 674.62K | NYSE | |||
| 26.94 | 27.08 | 26.62 | +0.18 | +0.67% | 1.18M | NYSE | |||
| 1.98 | 2.07 | 1.95 | +0.030 | +1.54% | 125.36K | NASDAQ | |||
| 1.32 | 1.555 | 1.00 | -1.230 | -48.24% | 58.84M | NASDAQ | |||
| 26.99 | 27.01 | 26.99 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 92.16 | 92.51 | 91.02 | +1.16 | +1.27% | 12.00M | NYSE | |||
| 127.91 | 128.88 | 125.97 | +1.28 | +1.01% | 19.13M | NASDAQ | |||
| 0.27 | 0.27 | 0.25 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 37.87 | 37.92 | 37.41 | +0.30 | +0.80% | 5.30K | NYSE | |||
| 19.42 | 19.55 | 18.62 | +0.440 | +2.32% | 2.70M | NYSE | |||
| 24.99 | 25.03 | 24.99 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 1.54 | 1.54 | 1.54 | 0.00 | 0.00% | 0.00 | OTC Markets |